In:
Cancer Medicine, Wiley, Vol. 3, No. 5 ( 2014-10), p. 1294-1301
Abstract:
We compared morphologic computed tomography ( CT )‐based to metabolic fluoro‐deoxy‐glucose ( FDG ) positron emission tomography ( PET )/ CT ‐based response evaluation in patients with metastatic colorectal cancer and correlated the findings with survival and KRAS status. From 2006 to 2009, patients were included in a phase II trial and treated with cetuximab and irinotecan every second week. They underwent FDG ‐ PET / CT examination at baseline and after every fourth treatment cycle. Response evaluation was performed prospectively according to Response Evaluation Criteria in Solid Tumors ( RECIST 1.0) and retrospectively according to Positron Emission Tomography Response Criteria in Solid Tumors ( PERCIST ). Best overall responses were registered. Sixty‐one patients were eligible for response evaluation. Partial response ( PR ) rate was 18%, stable disease ( SD ) rate 64%, and progressive disease ( PD ) rate 18%. Partial metabolic response ( PMR ) rate was 56%, stable metabolic disease rate 33%, and progressive metabolic disease ( PMD ) rate 11%. Response agreement was poor, κ ‐coefficient 0.19. Hazard ratio for overall survival for responders ( PR / PMR ) versus nonresponders ( PD / PMD ) was higher for CT ‐ than for FDG ‐ PET / CT evaluation. Within patients with KRAS mutations, none had PR but 44% had PMR . In conclusion, morphologic and metabolic response agreement was poor primarily because a large part of the patients shifted from SD with CT evaluation to PMR when evaluated with FDG ‐ PET / CT . Furthermore, a larger fraction of the patients with KRAS mutations had a metabolic treatment response.
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2014.3.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2659751-2
Bookmarklink